Buffer system and corresponding liquid preparation and application thereof
Patent Information
- Application Number
- CN202411191991.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-09-01
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-26
AI Technical Summary
The poor stability of AAV gene therapy vectors during production, storage and administration leads to a decrease in transduction efficiency and triggers adverse reactions during high dose systemic administration. The high osmotic pressure of existing preparations leads to an immune response, limiting its clinical application.
Develop a buffer system, including soluble salts, polyols and pH buffers, adjust the pH value of the solution between 7.0 and 8.0, reduce the osmotic pressure, prevent damage to virus particles during low temperature and freeze-thawing, and improve their stability. and dispersibility.
It significantly improves the stability and dispersion of AAV particles, reduces the aggregate content and free nucleic acid content, avoids adverse reactions caused by high osmotic pressure, expands its application scenarios, and ensures stability and safety under isosmotic pressure. sex.
Smart Images

Figure CN119015447A_ABST
Abstract
Citation Information
Patent Citations
Nucleic acid construct for treating hereditary coagulation factor deficiency disease and application of nucleic acid construct
CN117247973A
Nucleic acid constructs and uses thereof
CN117363656A
Formulations of highly purified viral particles
CN116323925A
Soluble thrombomodulin-containing composition
JP2000026309A
Improved pharmaceutical compositions containing adeno-associated viral vector
WO2022133324A1
